10 years’ experience with the pneumococcal quinolone moxifloxacin
Authors:
- Olaf BurkhardtOBOlaf Burkhardt
- Tobias WelteTWTobias Welte
- 1 August 2009
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Anti-infective Therapy
- Vol. 7 (6) , 645-668
Abstract
Moxifloxacin (MXF) is the latest broad-spectrum fluoroquinolone marketed worldwide. It has in vitro activity against a wide range of Gram-positive and Gram-negative pathogens including anaerobes and intracellular organisms, as well as strains resistant to beta-lactam or macrolide antibiotics. For relevant respiratory pathogens, MXF attains the threshold values of pharmacodynamic indices predictive of clinical efficacy and minimization of resistance development. On the other hand, due to its limited activity against Pseudomonas aeruginosa, it is less suitable for 'late-onset' nosocomial infections. In clinical trials, it has been found to be at least as effective and safe as comparators, while often showing higher bacteriological success rates. In some randomized studies MXF has shown superiority over comparator regimens in the treatment of patients with community-acquired pneumonia and acute bacterial exacerbations of chronic bronchitis. A consistent observation in many clinical trials of respiratory tract infections is the early onset of effect and a faster resolution of symptoms compared with standard therapy, possibly resulting from its fast distribution into tissue and high bactericidal activity leading to more rapid bacterial eradication. Although originally developed for respiratory tract infections, MXF over the years as been shown to be effective, and consequently received approval for additional indications.Keywords
This publication has 99 references indexed in Scilit:
- Repeated Administration of High-Dose Intermittent Rifapentine Reduces Rifapentine and Moxifloxacin Plasma ConcentrationsAntimicrobial Agents and Chemotherapy, 2008
- Non-susceptibility trends among Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections in the UK and Ireland, 1999-2007Journal of Antimicrobial Chemotherapy, 2008
- Clinical and microbiological efficacy of moxifloxacin versus amoxicillin/clavulanic acid in severe odontogenic abscesses: a pilot studyEuropean Journal of Clinical Microbiology & Infectious Diseases, 2008
- Comparison of the In Vitro Efficacies of Moxifloxacin and Amoxicillin against Listeria monocytogenesAntimicrobial Agents and Chemotherapy, 2008
- Effects of Rifampin and Multidrug Resistance Gene Polymorphism on Concentrations of MoxifloxacinAntimicrobial Agents and Chemotherapy, 2007
- Fluoroquinolone Resistance in Streptococcus pneumoniae : Area Under the Concentration-Time Curve/MIC Ratio and Resistance Development with Gatifloxacin, Gemifloxacin, Levofloxacin, and MoxifloxacinAntimicrobial Agents and Chemotherapy, 2007
- Are Broad-Spectrum Fluoroquinolones More Likely To Cause Clostridium difficile -Associated Disease?Antimicrobial Agents and Chemotherapy, 2006
- Randomized Controlled Trial of Moxifloxacin Compared With Piperacillin???Tazobactam and Amoxicillin???Clavulanate for the Treatment of Complicated Intra-abdominal InfectionsAnnals of Surgery, 2006
- Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): Efficacy and Safety of Moxifloxacin Therapy versus That of Levofloxacin TherapyClinical Infectious Diseases, 2006
- Efficacy and safety of sequential moxifloxacin for treatment of community-acquired pneumonia associated with atypical pathogensEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004